Genmab A/S GMAB 深 沪
已收盘 10-09 16:00:00 美东时间
37.07
+1.020
+2.83%
华盛通- 最 高37.15
- 今 开36.55
- 成交量 233.35万股
- 最 低 36.33
- 昨 收 36.05
- 总市值 2279.44万
- 52周最高 40.17
- 市盈率 静 24.06
- 换手率 0.38%
- 52周最低 23.62
- 委 比 84.79%
- 总股本 0.01亿
- 历史最高 49.07
- 量 比 0.35
- 振 幅 2.27%
- 历史最低 16.24
- 每 手 1
- 风险率 3.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
欧洲股市三连涨 油价和债券收益率回落提振风险偏好
欧洲股市连续第三个交易日上涨，油价回落和债券收益率下降提振了风险偏好。 斯托克欧洲600指数收涨0.5%。旅游股和汽车股跑赢大盘，电信和工业板块表现落后...
10-07 02:30
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
AbbVie flags $216M IPR&D and milestones expense for Q3
AbbVie (ABBV) said its Q3 financial results will likely include an acquired in-process research and development (IPR&D) and milestones expense of $216M on a pre-tax basis. As a result, GAAP and non-GA...
10-06 05:04
Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment
Genmab (GMAB) and AbbVie (ABBV) said that topline results from a phase 3 trial found that Epkinly (epcoritamab), in combination with standard of care cancer treatment known as R-CHOP, led to significa...
10-06 03:42
Guggenheim Maintains Buy on Genmab, Raises Price Target to $54
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $54.
10-05 20:59
Genmab Announces That Darwin Global Management Now Controls 3,188,361 Shares, 5.11% Of Voting Rights
As of September 28, 2026, Darwin through shares and ADRs held by certain investment funds and portfolios for which Darwin acts as investment manager, controls the voting rights attached to 3,188,361 shares in Genmab A/S, corresponding to 5.11% of the voting rights in Genmab A/S.
10-03 01:57
Genmab Grants New Employee Restricted Stock Units and Warrants
Genmab ( ($GMAB) ) has issued an update. On September 24, 2026, Genmab’s board ...
09-25 03:17
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
Gotistobart, an investigational CTLA-4-targeting immunotherapy, has shown promising results in a Phase 3 clinical trial for patients with squamous non-small cell lung cancer (NSCLC) who have progressed on prior immunotherapy and chemotherapy. The updated data from stage 1 of the PRESERVE-003 trial demonstrated a median overall survival (OS) of 18.5 months with gotistobart compared to 10.0 months with standard-of-care chemotherapy, nearly doubling...
09-14 08:00
